205 related articles for article (PubMed ID: 18797822)
1. Impact of 111In-DTPA-octreotide SPECT/CT fusion images in the management of neuroendocrine tumours.
Castaldi P; Rufini V; Treglia G; Bruno I; Perotti G; Stifano G; Barbaro B; Giordano A
Radiol Med; 2008 Oct; 113(7):1056-67. PubMed ID: 18797822
[TBL] [Abstract][Full Text] [Related]
2. Image fusion analysis of (99m)Tc-HYNIC-Tyr(3)-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours.
Gabriel M; Hausler F; Bale R; Moncayo R; Decristoforo C; Kovacs P; Virgolini I
Eur J Nucl Med Mol Imaging; 2005 Dec; 32(12):1440-51. PubMed ID: 16133384
[TBL] [Abstract][Full Text] [Related]
3. Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors.
Perri M; Erba P; Volterrani D; Lazzeri E; Boni G; Grosso M; Mariani G
Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):323-33. PubMed ID: 18480741
[TBL] [Abstract][Full Text] [Related]
4. Value of image fusion using single photon emission computed tomography with integrated low dose computed tomography in comparison with a retrospective voxel-based method in neuroendocrine tumours.
Amthauer H; Denecke T; Rohlfing T; Ruf J; Böhmig M; Gutberlet M; Plöckinger U; Felix R; Lemke AJ
Eur Radiol; 2005 Jul; 15(7):1456-62. PubMed ID: 15627182
[TBL] [Abstract][Full Text] [Related]
5. Incremental value of
Trogrlic M; Težak S
Nuklearmedizin; 2017 Jun; 56(3):97-107. PubMed ID: 28164207
[TBL] [Abstract][Full Text] [Related]
6. Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasms.
Pfannenberg AC; Eschmann SM; Horger M; Lamberts R; Vonthein R; Claussen CD; Bares R
Eur J Nucl Med Mol Imaging; 2003 Jun; 30(6):835-43. PubMed ID: 12682789
[TBL] [Abstract][Full Text] [Related]
7. 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients.
Pfeifer A; Knigge U; Binderup T; Mortensen J; Oturai P; Loft A; Berthelsen AK; Langer SW; Rasmussen P; Elema D; von Benzon E; Højgaard L; Kjaer A
J Nucl Med; 2015 Jun; 56(6):847-54. PubMed ID: 25952736
[TBL] [Abstract][Full Text] [Related]
8. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging.
Shi W; Johnston CF; Buchanan KD; Ferguson WR; Laird JD; Crothers JG; McIlrath EM
QJM; 1998 Apr; 91(4):295-301. PubMed ID: 9666953
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin receptor imaging in intracranial tumours.
Schmidt M; Scheidhauer K; Luyken C; Voth E; Hildebrandt G; Klug N; Schicha H
Eur J Nucl Med; 1998 Jul; 25(7):675-86. PubMed ID: 9662588
[TBL] [Abstract][Full Text] [Related]
10. Attenuation correction of somatostatin receptor SPECT by integrated low-dose CT: is there an impact on sensitivity?
Steffen IG; Mehl S; Heuck F; Elgeti F; Furth C; Amthauer H; Ruf J
Clin Nucl Med; 2009 Dec; 34(12):869-73. PubMed ID: 20139819
[TBL] [Abstract][Full Text] [Related]
11. Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
Ur E; Bomanji J; Mather SJ; Britton KE; Wass JA; Grossman AB; Besser GM
Clin Endocrinol (Oxf); 1993 May; 38(5):501-6. PubMed ID: 8101146
[TBL] [Abstract][Full Text] [Related]
12. Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours.
Van Binnebeek S; Vanbilloen B; Baete K; Terwinghe C; Koole M; Mottaghy FM; Clement PM; Mortelmans L; Bogaerts K; Haustermans K; Nackaerts K; Van Cutsem E; Verslype C; Verbruggen A; Deroose CM
Eur Radiol; 2016 Mar; 26(3):900-9. PubMed ID: 26162577
[TBL] [Abstract][Full Text] [Related]
13. Physiological Uptake in the Pancreatic Head on Somatostatin Receptor Scintigraphy Using [111In-DTPA]Octreotide: Incidence and Mechanism.
Brabander T; Teunissen J; Kwekkeboom D
Clin Nucl Med; 2017 Jan; 42(1):15-19. PubMed ID: 27775943
[TBL] [Abstract][Full Text] [Related]
14. Contribution of ¹¹¹In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours.
Sainz-Esteban A; Olmos R; González-Sagrado M; González ML; Ruiz MÁ; García-Talavera P; Gamazo C; Villanueva JG; Cobo A; de Luis D
Nucl Med Commun; 2015 Mar; 36(3):251-9. PubMed ID: 25369750
[TBL] [Abstract][Full Text] [Related]
15. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy.
Srirajaskanthan R; Kayani I; Quigley AM; Soh J; Caplin ME; Bomanji J
J Nucl Med; 2010 Jun; 51(6):875-82. PubMed ID: 20484441
[TBL] [Abstract][Full Text] [Related]
16. Thoracic and abdominal SPECT-CT image fusion without external markers in endocrine carcinomas. The Group of Thyroid Tumoral Pathology of Champagne-Ardenne.
Pérault C; Schvartz C; Wampach H; Liehn JC; Delisle MJ
J Nucl Med; 1997 Aug; 38(8):1234-42. PubMed ID: 9255157
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of a streamlined imaging protocol in technetium-99m-Tektrotyd somatostatin receptor SPECT/CT.
Al-Chalabi H; Cook A; Ellis C; Patel CN; Scarsbrook AF
Clin Radiol; 2018 Jun; 73(6):527-534. PubMed ID: 29397911
[TBL] [Abstract][Full Text] [Related]
18. Uptake in the pancreatic uncinate process on the 111In-octreotide scintigraphy: How to distinguish physiological from pathological uptake?
Ait Boudaoud A; Verges B; Petit JM; Tatulashvili S; Cochet A; Humbert O
Nucl Med Commun; 2017 Sep; 38(9):737-743. PubMed ID: 28704340
[TBL] [Abstract][Full Text] [Related]
19. Radiolabeled somatostatin analog scintigraphy in oncology and immune diseases: an overview.
Kwekkeboom DJ; Krenning EP
Eur Radiol; 1997; 7(7):1103-9. PubMed ID: 9265684
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide.
Westlin JE; Janson ET; Arnberg H; Ahlström H; Oberg K; Nilsson S
Acta Oncol; 1993; 32(7-8):783-6. PubMed ID: 8305227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
